news

MHRA approves COVID-19 Vaccine Moderna in 12-17-year olds

0
SHARES

The MHRA has approved the use of the Spikevax vaccine (formerly COVID-19 Vaccine Moderna) in children aged 12-17 years old.

COVID-19 Vaccine Moderna

The UK’s Medicines and Healthcare product Regulatory Agency (MHRA) have authorised an extension to the current approval of the Spikevax vaccine, formerly COVID-19 Vaccine Moderna, that allows its use in individuals aged 12-17 years.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

“I am pleased to confirm that that the COVID-19 vaccine made by Moderna has now been authorised in 12-17 year olds. The vaccine is safe and effective in this age group,” said MHRA Chief Executive Dr June Raine. “We have in place a comprehensive safety surveillance strategy for monitoring the safety of all UK-approved COVID-19 vaccines and this surveillance will include the 12- to 17-year age group.

“It is for the Joint Committee on Vaccination and Immunisation (JCVI) to advise on whether this age group should be vaccinated with the COVID-19 vaccine made by Moderna as part of the deployment programme.”

According to the MHRA, no new side effects were identified and the safety data in children was comparable with that seen in young adults. As in young adults, the majority of adverse events were mild to moderate and relating to reactogenicity, such as a sore arm or tiredness.

The MHRA has stated that this Conditional Marketing Authorisation (CMA) extension granted by the MHRA is valid in Great Britain only. It was approved via the European Commission (EC) Decision Reliance Route, wherein the marketing authorisation application made by the company references the decision made by the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP).

Spikevax was previously authorised in children aged 12-17 years in Northern Ireland under the CMA extension granted by the EMA on 23 July 2021 and is already authorised in the UK for adults aged 18 years and over.

Share via
Share via